Startups
Pulmocide is a UK-based biotechnology company developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Overview
Location
United Kingdom, England, London
Total raised
$174M
Investors 7
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| F-Prime Capital Partners | fprimecapital.com | |
| Adjuvant Capital | adjuvantcapital.com | |
| Jan 23, 2023 | Vivo Capital | vivocapital.com |
| SV Health Investors | svhealthinvestors.com | |
| Eight Roads | eightroads.com | |
| SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 27, 2021 | Series C round | $92M | |
| Mar 21, 2017 | Series B round | $30M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 6, 2022 | Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | |
| Dec 6, 2022 | Pulmocide Ltd - Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Strong support from high-quality new and existing investors provides capital for opelconazole development and pre-commercialization activities well beyond ongoing registration studies LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pulmocide... |
| Dec 6, 2021 | CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipients | |
| May 27, 2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suf... |
| May 27, 2021 | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma company focused on the development of novel tr... |
| May 27, 2021 | IP GROUP PLC IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| May 27, 2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | |
| May 27, 2021 | IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| May 27, 2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | London, UK, 27May2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 ... |
Show more
Reviews 0
FAQ about Pulmocide
How much funding has Pulmocide raised?
Pulmocide has raised $174M in total across 3 funding rounds.
What funding rounds has Pulmocide raised?
Parsers VC lists 3 funding rounds of Pulmocide, among them a Series C round of $92M on May 27, 2021 and a Series B round of $30M on Mar 21, 2017.
Who has invested in Pulmocide?
Parsers VC lists 7 investors of Pulmocide, among them Vivo Capital, F-Prime Capital Partners and Adjuvant Capital.
What has the press written about Pulmocide?
Parsers VC has collected 14 articles mentioning Pulmocide, among them “Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole” (Dec 6, 2022) and “Pulmocide Ltd - Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole” (Dec 6, 2022).
Is Pulmocide still active?
Yes, Pulmocide is active; its latest activity on Parsers VC dates from Apr 15, 2024.